The University of Oxford confirmed that the Covid-19 vaccine it’s developing with AstraZeneca Plc produced strong immune responses in older adults in an early study, with pivotal findings from the final phase of trials expected in the coming weeks.The results, published Thursday in The Lancet medical journal, shed more light on preliminary data released in recent months showing the experimental shot generated an immune response in older people, who are at highest risk of severe illness.
Researchers are still eagerly awaiting late-stage trial results that will show whether the Astra-Oxford vaccine can meet the high bar set by front-runners Pfizer Inc.